nach oben

Current Psychiatry Reports

Erschienen in:

01.09.2013 | Bipolar Disorders (WH Coryell, Section Editor)

Immunity, Inflammation, and Bipolar Disorder: Diagnostic and Therapeutic Implications

verfasst von: Nora Hamdani, Raphael Doukhan, Ozlem Kurtlucan, Ryad Tamouza, Marion Leboyer

Erschienen in: Current Psychiatry Reports | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Bipolar disorder is now known to be associated not only with highly prevalent co-occurring psychiatric and substance use disorders but also with medical comorbidities, such as cardiovascular diseases, diabetes mellitus, obesity and thyroid dysfunction. Inflammatory disturbances repeatedly observed in bipolar disorder, can explain some of the comorbidity between bipolar disorder and medical disorder. This revised perspective of bipolar disorders should promote the development of therapeutic tools. Immuno-inflammatory dysfunction may well represent a significant component of the underlying pathophysiology of the disorder. We therefore propose to review the immuno-inflammatory hypothesis in bipolar disorder considering the co-occurence with autoimmune diseases, immunological and inflammatory markers, as well as immuno-genetic markers which could lead to personalized treatments.

Bauer MS, Altshuler L, Evans DR, et al. Prevalence and distinct correlates of anxiety, substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder. J Affect Disord. 2005;85:301–15.PubMedCrossRef

• Leboyer M, Kupfer DJ. Bipolar disorder: new perspectives in health care and prevention. J Clin Psychiatry. 2010;71(12):1689–95. An original paper with useful advices.PubMedCrossRef

• Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord. 2012;141(1):1–10. A good review of comorbid diseases in bipolar disorder.PubMedCrossRef

Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6:368–73.PubMedCrossRef

Kupfer DJ. The increasing medical burden in medical disorder. JAMA. 2005;20:2528–30.CrossRef

Goldstein BI, Kem DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70(8):1078–90.PubMedCrossRef

Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008;10:788–97.PubMedCrossRef

Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009;60(2):147–56.PubMedCrossRef

Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–50.PubMedCrossRef

10.

Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011;23(1):40–7.PubMed

11.

Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S–60S.PubMed

12.

Laaksonen D, Lakka HM, Niskanen L, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070–7.PubMedCrossRef

13.

Lakka TA, Niskanen LK, Kumpusalo E, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.PubMedCrossRef

14.

Mc Intyre RS, Konarski JZ, Misener VL, et al. Bipolar disorder and diabete mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry. 2005;17(2):83–93.CrossRef

15.

Salvi V, D'Ambrosio V, Rosso G, Bogetto F, Maina G. Age-specific prevalence of metabolic syndrome in Italian patients with bipolar disorder. Psychiatry Clin Neurosci. 2011;65:47–54.PubMedCrossRef

16.

Miller BJ, Mellor A, Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain Behav Immun. 2013;31:82–9.PubMedCrossRef

17.

Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, et al. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry. 2008;20:131–7.PubMedCrossRef

18.

Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG. Mania and mortality: why the excess cardiovascular risk in bipolar disorder? 2009;11(6):475–480.

19.

Maina G, Salvi V, Vitalucci A, D’Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. J Affect Disord. 2008;110(1–2):149–55.PubMedCrossRef

20.

Birkenaes AB, Opjordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry. 2007;68(6):917–23.PubMedCrossRef

21.

Johannessen L, Strudsholm U, Foldager L, Munk-Jørgensen P. Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. J Affect Disord. 2006;95:13–7.PubMedCrossRef

22.

Angst F, Stassenm HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow up of 34–38 years. J Affect Disord. 2002;68:167–81.PubMedCrossRef

23.

Perris C, d'Ellia G. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand. 1996;164:172–89.

24.

Tsuang MT, Woolson RF, Fleming JA. Premature deaths in schizophrenia and affective disorders. An analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry. 1980;37(9):979–83.PubMedCrossRef

25.

• Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010;12(6):638–46. Good topic for autoimmunity in bipolar disorder with interesting data.PubMedCrossRef

26.

Vonk R, Van der Schot AC, Kahn RS, et al. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol Psychiatry. 2007;62(2):135–40.PubMedCrossRef

27.

Cassidy F, Ahearm E, Carroll BJ. Elevated frequency of diabete mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156(9):1417–20.PubMed

28.

Kupka RW, Regeer EJ. Bipolar mood disorders. Ned Tijdschr Geneeskd. 2007;151(41):2256–60.PubMed

29.

Severance EG, Dickerson FB, Halling M, et al. Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. Schizophr Res. 2010;118(1–3):240–7.PubMedCrossRef

30.

Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem. 2009;48:111–36.PubMedCrossRef

31.

Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med. 2006;119(2):166.e17–28.CrossRef

32.

Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–86.PubMedCrossRef

33.

Pasco JA, Nicholson GC, Williams LJ, et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry. 2010;197:372–7.PubMedCrossRef

34.

Wadee AA, Kuschke RH, Wood LA, et al. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol. 2002;17(4):175–9.PubMedCrossRef

35.

Huang TL, Lin FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):370–2.PubMedCrossRef

36.

Dickerson F, Stallings C, Origoni A, et al. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(4):952–5.PubMedCrossRef

37.

De Berardis D, Conti CM, Campanella D, Carano A, et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol. 2008;21(2):319–24.PubMed

38.

Cunha AB, Andreazza AC, Gomes FA, Frey BN, et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2008;258(5):300–4.PubMedCrossRef

39.

Tsai SY, Chen KP, Yang YY, et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry. 1999;45(8):989–94.PubMedCrossRef

40.

Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104(1–3):91–5.PubMedCrossRef

41.

Ortiz-Dominguez A, Hernandez ME, Berlanga C, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9(6):596–602.PubMedCrossRef

42.

O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90(2–3):263–7.PubMedCrossRef

43.

Rapaport MH, Guylai L, Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J Psychiatr Res. 1999;33(4):335–40.PubMedCrossRef

44.

Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord. 2012;136(1–2):110–6.PubMedCrossRef

45.

Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun. 2009;23(8):1079–82.PubMedCrossRef

46.

Knijff EM, Breunis MN, Kupka RW, et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007;9(7):743–53.PubMedCrossRef

47.

Mollace V, Muscoli C, Masini E, et al. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev. 2005;57(2):217–52.PubMedCrossRef

48.

Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 2009;34(4):263–71.PubMed

49.

Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15(4):384–92.PubMedCrossRef

50.

Kapczinski F, Dias VV, Kauer-Sant'Anna M, Brietzke E, Vazquez GH, Vieta E, et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1366–71.PubMedCrossRef

51.

Berk M, Conus P, Lucas N, Hallam K, Malhi GS, Dodd S, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 2007;9(7):671–8.PubMedCrossRef

52.

• Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144(1–2):16–27. doi:10.1016/j.jad.2012.06.010. A recent meta-analysis to assess the role of cytokines in bipolar disorder.PubMedCrossRef

53.

Pawelec G, Barnett Y, Forsey R, et al. T cells and aging. Front Biosci. 2002;7:d1056–183.PubMed

54.

Czerski PM, Rybakowski F, Kapelski P, Rybakowski JK, et al. Association of tumor necrosis factor -308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology. 2008;57(1–2):88–94.PubMedCrossRef

55.

Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002;20(5 Suppl 27):S1–S13.PubMed

56.

Hwang JP, Tsai SJ, Hong CJ, et al. Interleukin-1 beta -511C/T genetic polymorphism is associated with age of onset of geriatric depression. Neuromolecular Med. 2009;11(4):322–7.PubMedCrossRef

57.

Papiol S, Molina V, Desco M, et al. Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin-1 beta gene (2q13). Genes Brain Behav. 2008;7(7):796–801.PubMedCrossRef

58.

Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry. 65(4):395–407.

59.

Thorsby E, Lie BA. HLA associated genetic predisposition to autoimmune diseases: genes involved and possible mechanisms. Transpl Immunol. 2005;14(3–4):175–82.PubMedCrossRef

60.

Biederman J, Keller M, Lavori P, et al. HLA haplotype A26-B38 in affective disorders: lack of association. Biol Psychiatry. 1987;22(2):221–4.PubMedCrossRef

61.

Sorokina TT, Evsegneev RA, Levin VI, Semenov GV. Features of the distribution of HLA-antigens among patients with endogenous psychose. Zh Nevropatol Psikhiatr Im S S Korsakova. 1987;87(6):885–8.PubMed

62.

• Debnath M, Busson M, Jamain S, et al. The HLA-G low expressor genotype is associated with protection against bipolar disorder. Hum Immunol. 2013;74(5):593–7. Recent data for the implication of the HLAG in bipolar disorder.PubMedCrossRef

63.

Biederman J, Keller M, Lavori P, Harmatz J, Knee D, Dubey D, et al. HLA haplotype A26-B38 in affective disorders: lack of association. Biol Psychiatry. 1987;22(2):221–4.PubMedCrossRef

64.

Bozikas VP, Anagnostouli MC, Petrikis P, et al. Familial bipolar disorder and multiple sclerosis: a three-generation HLA family study. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(5):835–9.PubMedCrossRef

65.

Kaminsky Z, Tochigi M, Jia P, et al. A multi-tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar disorder. Mol Psychiatry. 2012;17(7):728–40. doi:10.1038/mp.2011.64.PubMedCrossRef

66.

Griffiths DJ. Endogenous retroviruses in the human genome sequence. Genome Biol. 2001;2(6):reviews 1017.CrossRef

67.

Venter A. New protein blocks HIV. Trends Microbiol. 2001;9(3):110.PubMedCrossRef

68.

Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. Epstein–Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity. 2001;15(4):579–89.PubMedCrossRef

69.

• Hamdani N, Daban-Huard C, Lajnef M, et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord. 2013;148(2–3):444–8. Recent data presenting the link between infectious agents and bipolar disorder.PubMedCrossRef

70.

Frank O, Giehl M, Zheng C, Hehlmann R, Leib-Mosch C, Seifarth W. Human endogenous retrovirus expression profiles in samples from brains of patients with schizophrenia and bipolar disorder. J Virol. 2005;79(17):10890–901.PubMedCrossRef

71.

Weis S, Llenos IC, Sabunciyan S, et al. Reduced expression of human endogenous retrovirus (HERV)-W GAG protein in the cingulate gyrus and hippocampus in schizophrenia, bipolar disorder, and depression. J Neural Transm. 2007;114(5):645–55.PubMedCrossRef

72.

Perron H, Mekaoui L, Bernard C, Veas F, Stefas I, Leboyer M. Endogenous retrovirus type W GAG and envelope protein antigenemia in serum of schizophrenic patients. Biol Psychiatry. 2008;64(12):1019–23.PubMedCrossRef

73.

• Perron H, Hamdani N, Faucard R, et al. Molecular characteristics of Human Endogenous Retrovirus type-W (HERV-W) in schizophrenia and bipolar disorder. Transl Psychiatry. 2012. doi:10.1038/tp.2012.125. The only study involving the HERV in bipolar disorder.PubMed

74.

Antony JM, van Marle G, Opii W, Butterfield DA, Mallet F, Yong VW, et al. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci. 2004;7(10):1088–95.PubMedCrossRef

75.

Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157(5):683–94.PubMedCrossRef

76.

Kronfol Z, LeMay L, Nair M, Kluger M. Electroconvulsive therapy increases plasma levels of interleukin-6. Ann NY Acad Sci. 1990;594:463–5.CrossRef

77.

Boufidou F, Nikolaou C, Alevizos B, Liappas IA, Christodoulou GN. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord. 2004;82(2):309–13.PubMedCrossRef

78.

Maes M, Calabrese J, Jayathilake K, Meltzer HY. Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Res. 1997;71(2):67–76.PubMedCrossRef

79.

Rapaport MH. Immune parameters in euthymic bipolar patients and normal volunteers. J Affect Disord. 1994;32(3):149–56.PubMedCrossRef

80.

Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology. 1997;35(3):123–7.PubMedCrossRef

81.

Bubak-Satora M, Skowron-Cendrzak A, Kubera M. The effect of lithium chloride treatment on cell-mediated immunity in mice. Folia Biol (Krakow). 1991;39(1–4):21–4.

82.

Krause I, Cohen J, Blank M, et al. Distribution of two common idiotypes of anticardiolipin antibodies in sera of patients with primary antiphospholipid syndrome, systemic lupus erythematosus and monoclonal gammopathies. Lupus. 1992;1(2):91–6.PubMedCrossRef

83.

Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003;62(3):237–44.PubMedCrossRef

84.

Vale S, Espejel MA, Dominguez JC. Amantadine in depression. Lancet. 1971;2(7721):437.PubMedCrossRef

85.

Bode L, Durrwald R, Rantam FA, et al. First isolates of infectious human Borna disease virus from patients with mood disorders. Mol Psychiatry. 1996;1(3):200–12.PubMed

86.

Dietrich DE, Bode L, Spannhuth CW, et al. Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disord. 2000;2(1):65–70.PubMedCrossRef

87.

Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry. 1999;32(2):47–55.PubMedCrossRef

88.

Muller N, Schwarz MJ, Dehning S, Douhe A, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680–4.PubMedCrossRef

89.

Casolini P, Catalani A, Zuena AR, Angelucci L. Inhibition of COX-2 reduce the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res. 2002;68(3):337–43.PubMedCrossRef

Titel: Immunity, Inflammation, and Bipolar Disorder: Diagnostic and Therapeutic Implications
verfasst von: Nora Hamdani
Raphael Doukhan
Ozlem Kurtlucan
Ryad Tamouza
Marion Leboyer
Publikationsdatum: 01.09.2013
Verlag: Springer US
Erschienen in: Current Psychiatry Reports / Ausgabe 9/2013
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-013-0387-y

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2013

The Link Between Suicide and Insomnia: Theoretical Mechanisms

Globalization and Cognitive Enhancement: Emerging Social and Ethical Challenges for ADHD Clinicians

Consensual Sadomasochistic Sex (BDSM): The Roots, the Risks, and the Distinctions Between BDSM and Violence

A Review of Recent Literature Employing Electroencephalographic Techniques to Study the Pathophysiology, Phenomenology, and Treatment Response of Schizophrenia